CervoMed Inc. — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2021-11-01

Reporting Person: Cobuzzi Robert Joseph Jr. (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Common Stock	M	16350	—	Acquired	30350	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Restricted Stock Units	$	M	16350	Disposed		Common Stock (16350)	Direct

Footnotes

F1: On November 1, 2021, the Reporting Person received 16,350 shares in connection with the vesting of previously awarded restricted stock units, each unit representing a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continuing service with the Issuer, the remaining restricted stock units will vest in equal, tri-monthly installments.